CalciMedica Inc. is a clinical-stage biopharmaceutical company. It focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica Inc. is based in LA JOLLA, Calif.
Revenue (Most Recent Fiscal Year) | -- |
Net Income (Most Recent Fiscal Year) | $-13.70M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.87 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -146.23% |
Return on Assets (Trailing 12 Months) | -94.70% |
Current Ratio (Most Recent Fiscal Quarter) | 5.34 |
Quick Ratio (Most Recent Fiscal Quarter) | 5.34 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $1.07 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.34 |
Earnings per Share (Most Recent Fiscal Year) | $-1.82 |
Diluted Earnings per Share (Trailing 12 Months) | $-1.19 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 13.97M |
Free Float | 8.17M |
Market Capitalization | $27.94M |
Average Volume (Last 20 Days) | 0.03M |
Beta (Past 60 Months) | 1.24 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 41.55% |
Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |